汉防己甲素抑制一氧化氮合酶活性防治肝硬化门脉高压症  

Tetrandrine Prevents Cirrhosis and Portal Hypertension by Inhibiting the Enzymatic Activity of Nitric Oxide Synthase

作　　者：王海[1] 周怀文[1] 余秀专[1] 

机构地区：[1]贵阳医学院附院外科,贵阳 550004

出　　处：《贵阳医学院学报》2000年第4期335-338,共4页Journal of Guiyang Medical College

摘　　要：为探讨汉防己甲素抑制肝纤维化和改善门脉高动力循环的作用机制 ,分 3组测定肝组织中一氧化氮合酶 (NOS)活性和血清中一氧化氮 (NO) ,观察门静脉血流量 (PVF)、门静脉压力 (PVP)、门静脉阻力 (PVR)及肝脏病理学改变。结果显示 ,钙拮抗剂汉防己甲素显著抑制NOS活性和NO生成 ,明显降低PVP和PVF ,病理切片显示汉防己甲素明显防止肝细胞坏死 ,阻止肝纤维化发展。提示抑制NOS活性和NO生成是汉防己甲素防治肝硬化门脉高压症的主要作用机理。To investigate the mechanism of inhibiting hepatic fibrosis and improving the portal venous high dynamic circulation by tetrandrine,we test the enzymatic activity of NOS in hepatic tissue and NO in the serum and investigate the change of portal venous flow(PVF),portal venons pressure(PVP), portal venous resistance(PVR)and pathologic examination from three groups. Tetrandrine is calcium antagonists,which significantly inhibited the enzymatic activity of NOS and NO production.PVP and PVF decreased largely by tetrandrine.Pathologic examination indicated that tetrandrine had an obvious effect on preventing the necrosis of hepatic cells and delaying the development of hepatic fibrosis. The vitally preventing mechanism of cirrhosis and portal hypertension is inhibiting the enzymatic activity of NOS.

关 键 词：汉防己甲素 肝硬化 一氧化氮合酶 门脉高压症 

分 类 号：R575.210.5[医药卫生—消化系统]